NGeneBio
Key metrics
Earnings
| Revenue, Q3 2026 | ₩13.4bn |
|---|---|
| Revenue QoQ | +7.9% |
| Revenue YoY | +147.5% |
| Operating income, Q3 2026 | -₩1.3bn |
| Operating income QoQ | -10.5% |
| Operating income YoY | +20.5% |
Share buybacks
| Buyback decided, last 3 months | ₩0 |
|---|---|
| Buyback decided, last 3 months, % of shares | 0.0% |
| Shares acquired, last 3 months | ₩0 |
| Shares acquired, last 3 months, % of shares | 0.0% |
| Treasury shares cancelled, last 3 months | ₩0 |
| Treasury shares cancelled (number), last 3 months | 0 shares |
| Treasury shares cancelled, last 3 months, % of shares | 0.0% |
| Buyback decided, last 12 months | ₩0 |
| Buyback decided, last 12 months, % of shares | 0.0% |
| Shares acquired, last 12 months | ₩0 |
| Shares acquired, last 12 months, % of shares | 0.0% |
| Treasury shares cancelled, last 12 months | ₩0 |
| Treasury shares cancelled (number), last 12 months | 0 shares |
| Treasury shares cancelled, last 12 months, % of shares | 0.0% |
Potential dilution
| CB/BW/EB issued, last 12 months | ₩0 |
|---|---|
| Rights offering new shares, last 12 months | 15,150,000 shares |
| Potential new shares, last 12 months | 15,150,000 shares |
| Potential new shares, % of shares | 94.2% |
| Conversion price adjustments, last 12 months | 0 |
Supply contracts
| Supply contracts, last 12 months | ₩0 |
|---|---|
| Supply contracts vs prior-year revenue | 0.0% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Disclosure activity
| DART filings, last 3 months | 24 |
|---|---|
| DART filings, previous 3 months | 28 |
Insider transactions
| Open-market buys, last 12 months (shares) | 42,710 shares |
|---|---|
| Open-market buys, last 12 months (amount) | ₩100m |
| Open-market sells, last 12 months (shares) | 0 shares |
| Open-market sells, last 12 months (amount) | ₩0 |
| Net open-market buying, last 12 months (shares) | 42,710 shares |
| Insiders who bought, last 12 months | 1 |
Insider transactions (last 12 months)
Open-market buys: 42,710 shares (₩100m). Open-market sells: 0 shares (₩0). Net open-market buying: +42,710 shares. Insiders who bought: 1.
| Trade date | Insider (role) | Type | Shares | Price | Amount | |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Eseueichihelseukeeotuja1hojohap (Controlling shareholder) | Other (OTC sell) | -785,559 shares | — | — | |
| Aug 4, 2026 | Eseueichihelseukeeotuja1hojohap (Controlling shareholder) | Other (Other increase) | +1,571,118 shares | ₩1,074 | ₩1.7bn | |
| Jul 29, 2026 | Kim Min-sik (Registered director) | Open-market buy | +30,208 shares | ₩2,380 | ₩72m | |
| Jul 28, 2026 | Kim Min-sik (Registered director) | Open-market buy | +12,502 shares | ₩2,250 | ₩28m | |
| Jun 25, 2026 | Eseueichihelseukeeotuja1hojohap (Controlling shareholder) | Other (Capital reduction) | -3,923,853 shares | — | — |
Annual financials
| Year | Revenue | Operating income |
|---|---|---|
| 2025 | ₩21.2bn | -₩8.3bn |
| 2024 | ₩5.7bn | -₩16.1bn |
| 2023 | ₩4.4bn | -₩13.4bn |
Filing timeline
-
NGeneBio to acquire Solar AM Holdings shares for ₩2.0bn
NGeneBio plans to acquire 22,000 shares of Solar AM Holdings Co., Ltd. for ₩2.0bn, equal to 6.7% of equity, which would bring its stake to 100.0%. The expected date is Nov 23, 2026. The stated purpose is to expand into renewable energy, including solar power plant engineering, procurement and construction (EPC) and power plant operation.
-
NGeneBio plans third-party allotment of 6,000,000 new shares
NGeneBio filed a rights offering for 6,000,000 new shares through third-party allotment, equal to 37.3% of existing shares. The issue amount is ₩6.0bn, with funds intended as operating funds. The amount equals 28.2% of FY2025 revenue by our calculation.
-
NGeneBio plans third-party allotment of 2,000,000 new shares
NGeneBio filed plans to issue 2,000,000 new shares through a third-party allotment, equal to 12.4% of existing shares. The issue amount is ₩2.0bn, with funds earmarked for debt repayment. By our calculation, the amount equals 9.4% of FY2025 revenue.